Pembrolizumab plus lenvatinib for all advanced endometrial cancer? Maybe not

被引：1
|
作者：
Paulino, Eduardo [1 ]
机构：
[1] Brazilian Natl Canc Inst, BR-20081250 Rio De Janeiro, Brazil
来源：
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER | 2022年 / 32卷 / 04期
关键词：
D O I：
10.1136/ijgc-2022-003419
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：579 / 579
页数：1
相关论文
共 50 条
  • [21] Treatment with lenvatinib plus pembrolizumab in recurrent or advanced endometrial cancer: A systematic review and meta-analysis
    Moraes, Francisco Cezar A.
    Vilbert, Maysa
    Carnevalli, Sarah Vitoria B.
    Almeida, Gustavo de Oliveira
    Feio, Danielle
    Stecca, Carlos
    Da Costa, Alexandre Andre B. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [22] New drug approval: Pembrolizumab plus lenvatinib in second line for patients with advanced or recurrent endometrial cancer
    De Jesus, Clara
    Rodrigues, Manuel
    BULLETIN DU CANCER, 2022, 109 (7-8) : 740 - 741
  • [23] A pivotal role of interdisciplinary team medicine in lenvatinib plus pembrolizumab therapy against advanced endometrial cancer
    Sonoda, Kenzo
    Sadamatsu, Yukiko
    Ishibashi, Yuka
    Okadome, Masao
    Katsuma, Shinichiro
    Nio, Ai
    Murakami, Takeshi
    Yamaguchi, Shinichiro
    Nagayama, Rina
    Ariyoshi, Kazuya
    Saito, Toshiaki
    ANNALS OF ONCOLOGY, 2023, 34 : S1463 - S1463
  • [24] Lenvatinib plus Pembrolizumab Combination Therapy for Advanced or Recurrent Endometrial Cancer: A Single-Center, Retrospective Analysis
    Tochigi, Mikako
    Shigeta, Shogo
    Shimada, Muneaki
    Miyahara, Shuko
    Hasegawa-Minato, Junko
    Shibuya, Yusuke
    Ishibashi, Masumi
    Hashimoto, Chiaki
    Tokunaga, Hideki
    Yaegashi, Nobuo
    TOHOKU JOURNAL OF EXPERIMENTAL MEDICINE, 2024, 262 (02): : 85 - 95
  • [25] Lenvatinib (LEN) plus pembrolizumab (PEMBRO) for early-line treatment of advanced/recurrent endometrial cancer (EC)
    Makker, Vicky
    Taylor, Matthew H.
    Aghajanian, Carol
    Oaknin, Ana
    Mier, James
    Cohn, Allen L.
    Romeo, Margarita
    Bratos, Raquel
    Brose, Marcia S.
    Di Simone, Christopher
    Messing, Mark
    Dutta, Lea
    Ren, Min
    Schmidt, Emmett V.
    Orlowski, Robert
    McKenzie, Jodi A.
    Gillis, Kathryn
    Young, Louise
    Herraez, Antonio Casado
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2020, 16 : 133 - 134
  • [26] Cost effectiveness of pembrolizumab plus lenvatinib compared with chemotherapy for treating previously treated advanced endometrial cancer in Sweden
    Ralph, Lewis
    Young, Kate
    Upadhyay, Navneet
    Prabhu, Vimalanand Shrikant
    Ljungcrantz, Christina
    Massaad, Rachid
    Xu, Ruifeng
    Giertz, Anna
    Merchant, Adil
    Orlowski, Robert
    Duska, Linda
    JOURNAL OF MEDICAL ECONOMICS, 2024, 27 (01) : 483 - 491
  • [27] Lenvatinib (LEN) plus pembrolizumab (PEMBRO) for early-line treatment of advanced/recurrent endometrial cancer (EC).
    Makker, Vicky
    Taylor, Matthew H.
    Aghajanian, Carol
    Oaknin, Ana
    Mier, James
    Lee Cohn, Allen
    Romeo, Margarita
    Bratos, Raquel
    Brose, Marcia S.
    DiSimone, Christopher
    Messing, Mark
    Dutta, Lea
    Ren, Min
    Schmidt, Emmett, V
    Orlowski, Robert
    Alicia McKenzie, Jodi
    Gillis, Kathryn
    Casado Herraez, Antonio
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [28] Expression of estrogen receptor is a negative predictive biomarker for immunotherapy with lenvatinib plus pembrolizumab for advanced endometrial cancer with pMMR
    Fujii, H.
    Nishikawa, T.
    Yoshida, H.
    Ozawa, R.
    Hoshino, M.
    Saito, A.
    Ito, M.
    Kita, S.
    Maejima, A.
    Kojima, Y.
    Sudo, K.
    Shimoi, T.
    Yonemori, K.
    ANNALS OF ONCOLOGY, 2023, 34 : S1592 - S1593
  • [29] Esophagitis as a complication of the combination of lenvatinib and pembrolizumab for advanced endometrial cancer: A case report
    Fellouah, Massine
    Auclair, Marie-Helene
    Fortin, Suzanne
    Berdugo, Jeremie
    de Guerke, Lara
    GYNECOLOGIC ONCOLOGY REPORTS, 2023, 49
  • [30] Lenvatinib and pembrolizumab in advanced gastric cancer
    Cascinu, Stefano
    LANCET ONCOLOGY, 2020, 21 (08): : 1004 - 1005
12345